News – Page 941 – Endpoints News

In surprise switch, Bristol-Myers is selling off blockbuster Otezla, promising to complete Celgene acquisition — ...

6 years ago

Bristol-Myers star Opdivo fails survival test in a matchup with Nexavar aimed at shaking up the big HCC market

6 years ago

In $86M IPO pitch, Mirum spells out plans to turn Shire discards into orphan liver drug successes

6 years ago

FDA spurns hay fever drug from India's Glenmark

6 years ago

Oxford, Evotec ramp up LAB10x with AI experts at Sensyne — focused on biotech spinouts

6 years ago

Why would the FDA approve another controversial drug to spur a woman’s libido with these data? And why no expert ...

6 years ago

Following news of job cuts in European R&D ops, Sanofi confirms it’s offering US workers an 'early exit'

6 years ago

ICER goes after Novartis for overpricing MS drug; Valneva, GlaxoSmithKline breaks vaccine pact

6 years ago

Maze interim chief Charles Homcy passes baton to Jason Coloma; William Collier tapped as CEO of Arbutus

6 years ago

Regeneron/Sanofi's antibody underwhelms in asthma study — shares of rival AnaptysBio pay the price

6 years ago

Green-lighted in Japan, FDA quickly spurns Daiichi Sankyo's flawed application for AML drug

6 years ago

J&J's Esketamine, at current price, is 'low value for money' — ICER

6 years ago

Which top 10 big pharmas have the most to gain — or lose — over the next 5 years?

6 years ago

HIV, pneumococcal — and what? Merck's unexpected pipeline highlight excites a little biotech

6 years ago

After years of claims and accusations, fraudster Martin Shkreli settles up with Retrophin

6 years ago

Roche/Exelixis' Cotellic fizzles in pivotal melanoma study

6 years ago

NEJM appoints Eric Rubin to succeed Jeffrey Drazen as EIC; Amphastar prevails against Momenta/Sandoz in years-long ...

6 years ago

'Our legacy matters': Merck maps out Keytruda kingdom while spotlighting advances in vaccines, hospital care

6 years ago

Eli Casdin backs Codexis' platform tech with $50M equity buy

6 years ago

Investors pony up $476M for the latest round of biotech IPOs to hit the Street

6 years ago

Verastem CEO Forrester steps to the exit as the board hunts commercial-savvy exec for the beleaguered biotech

6 years ago

Who’s next in line to succeed Ken Frazier as CEO of the Keytruda-blessed Merck?

6 years ago

In starved antibiotic field, Melinta soars as FDA grants speedy drug review

6 years ago

Analyst call with Allergan execs stokes anticipation of a plan to split the company in ‘a month or two’

6 years ago

First page Previous page 938 939 940941942 943 944 Next page Last page